[go: up one dir, main page]

MX2014002949A - Compuesto de imidazopiridina, composiciones y metodos de uso. - Google Patents

Compuesto de imidazopiridina, composiciones y metodos de uso.

Info

Publication number
MX2014002949A
MX2014002949A MX2014002949A MX2014002949A MX2014002949A MX 2014002949 A MX2014002949 A MX 2014002949A MX 2014002949 A MX2014002949 A MX 2014002949A MX 2014002949 A MX2014002949 A MX 2014002949A MX 2014002949 A MX2014002949 A MX 2014002949A
Authority
MX
Mexico
Prior art keywords
methods
compositions
imidazopyridine compounds
formulas
compound
Prior art date
Application number
MX2014002949A
Other languages
English (en)
Inventor
Birong Zhang
Vickie Hsiao-Wei Tsui
Yingjie Lai
Liangjun
Steven R Magnuson
Kirk D Robarge
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014002949A publication Critical patent/MX2014002949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a inhibidores de TYK2 de Fórmulas (la-Ib), estereoisómeros o sales de los mismos farmacéuticamente aceptables, en donde A, X, Ra, R1, R2, R4, R5 y R16 son definidos en la presente, una composición farmacéutica que incluye un compuesto de Fórmula (la-Ib) y un portador, adyuvante o vehículo farmacéuticamente aceptable, y métodos para usar el compuesto o composición en la terapia de enfermedades inflamatorias.
MX2014002949A 2011-09-20 2012-09-19 Compuesto de imidazopiridina, composiciones y metodos de uso. MX2014002949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536932P 2011-09-20 2011-09-20
PCT/EP2012/068380 WO2013041539A1 (en) 2011-09-20 2012-09-19 Imidazopyridine compounds, compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2014002949A true MX2014002949A (es) 2014-04-30

Family

ID=46963696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002949A MX2014002949A (es) 2011-09-20 2012-09-19 Compuesto de imidazopiridina, composiciones y metodos de uso.

Country Status (11)

Country Link
US (1) US20140206702A1 (es)
EP (1) EP2758397A1 (es)
JP (1) JP2014526538A (es)
KR (1) KR20140082710A (es)
CN (1) CN103827115A (es)
BR (1) BR112014006643A2 (es)
CA (1) CA2845409A1 (es)
HK (1) HK1198365A1 (es)
MX (1) MX2014002949A (es)
RU (1) RU2014113236A (es)
WO (1) WO2013041539A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012035039A1 (en) 2010-09-15 2012-03-22 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
RU2690853C2 (ru) 2014-09-02 2019-06-06 Пьер Фабр Медикамент Производные изохинолинона, полезные для лечения рака
ES3028873T3 (en) 2015-01-17 2025-06-20 Univ Texas Small molecules for the treatment of primary cancer and cancer metastasis
PL3868741T3 (pl) 2015-10-07 2024-01-29 Sumitomo Pharma Co., Ltd. Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu
WO2019079691A1 (en) 2017-10-19 2019-04-25 Jean Jiang SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
JP6557436B1 (ja) 2018-03-12 2019-08-07 アッヴィ・インコーポレイテッド チロシンキナーゼ２媒介性シグナル伝達の阻害剤
US12509430B2 (en) 2020-02-14 2025-12-30 President And Fellows Of Harvard College Inhibitors of nicotinamide N-methyltransferase, compositions and uses thereof
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JP2975679B2 (ja) 1989-09-08 1999-11-10 ザ・ジョーンズ・ホプキンス・ユニバーシティ ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
EP0772609B1 (en) 1994-07-21 1999-02-24 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GEP20012442B (en) 1996-04-12 2001-05-25 Warner Lambert Co Irreversible Inhibitors of Tyrosine Kinases
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7763634B2 (en) * 2006-06-09 2010-07-27 Merck & Co., Inc. Inhibitors of janus kinases
WO2008043019A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
JP2010507581A (ja) * 2006-10-20 2010-03-11 ナームローゼ・フエンノートチヤツプ・オルガノン ＰＫＣ−θ阻害薬としてのプリン類
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds

Also Published As

Publication number Publication date
WO2013041539A1 (en) 2013-03-28
HK1198365A1 (en) 2015-04-10
CA2845409A1 (en) 2013-03-28
JP2014526538A (ja) 2014-10-06
EP2758397A1 (en) 2014-07-30
CN103827115A (zh) 2014-05-28
KR20140082710A (ko) 2014-07-02
BR112014006643A2 (pt) 2017-04-04
RU2014113236A (ru) 2015-10-27
US20140206702A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
MX2014002949A (es) Compuesto de imidazopiridina, composiciones y metodos de uso.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
MX2013012588A (es) Inhibidores de cinasa.
MX2013011330A (es) Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso.
JO3111B1 (ar) ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttk
TN2015000034A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
WO2013004995A8 (en) Pyrimidinone compounds and their use
PH12013501800A1 (en) Tricyclic gyrase inhibitors
GB201209587D0 (en) Therapeutic compounds
MX340574B (es) Imidazo pirazinas.
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX347928B (es) Derivados de fenetilsulfona isoindolina y su uso.
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
TN2014000060A1 (en) Benzothiazolone compound
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.